临床麻醉学杂志
臨床痳醉學雜誌
림상마취학잡지
THE JOURNAL OF CLINICAL ANESTHESIOLOGY
2010年
2期
160-161
,共2页
盐酸戊乙奎醚%慢性阻塞性肺病%呼吸力学
鹽痠戊乙奎醚%慢性阻塞性肺病%呼吸力學
염산무을규미%만성조새성폐병%호흡역학
Penehyclidine%Chronic obstructive pulmonary disease%Respiratory mechanics
目的 研究应用盐酸戊乙奎醚对慢性阻塞性肺病(chronic obstructive pulmonary dis-ease,COPD)病人气管内插管应用呼吸机后呼吸力学参数的影响.方法 COPD病人66例随机均分为两组:盐酸戊乙奎醚组(Ⅰ组):气管插管应用呼吸机前静注盐酸戊乙奎醚1 mg;对照组(Ⅱ组):不给予任何支气管扩张药物.分别观察并监测气管内插管应用呼吸机后1、4和6 h的呼吸力学参数(气道压力、气道阻力和胸肺顺应性).结果 Ⅰ组各个时间点的气道峰压、气道平台压以及气道阻力明显低于Ⅱ组(P<0.05),而胸肺顺应性明显高于Ⅱ组(P<0.05).结论 盐酸戊乙奎醚可明显降低COPD病人气管内插管后的气道压力和气道阻力,增加胸肺顺应性.
目的 研究應用鹽痠戊乙奎醚對慢性阻塞性肺病(chronic obstructive pulmonary dis-ease,COPD)病人氣管內插管應用呼吸機後呼吸力學參數的影響.方法 COPD病人66例隨機均分為兩組:鹽痠戊乙奎醚組(Ⅰ組):氣管插管應用呼吸機前靜註鹽痠戊乙奎醚1 mg;對照組(Ⅱ組):不給予任何支氣管擴張藥物.分彆觀察併鑑測氣管內插管應用呼吸機後1、4和6 h的呼吸力學參數(氣道壓力、氣道阻力和胸肺順應性).結果 Ⅰ組各箇時間點的氣道峰壓、氣道平檯壓以及氣道阻力明顯低于Ⅱ組(P<0.05),而胸肺順應性明顯高于Ⅱ組(P<0.05).結論 鹽痠戊乙奎醚可明顯降低COPD病人氣管內插管後的氣道壓力和氣道阻力,增加胸肺順應性.
목적 연구응용염산무을규미대만성조새성폐병(chronic obstructive pulmonary dis-ease,COPD)병인기관내삽관응용호흡궤후호흡역학삼수적영향.방법 COPD병인66례수궤균분위량조:염산무을규미조(Ⅰ조):기관삽관응용호흡궤전정주염산무을규미1 mg;대조조(Ⅱ조):불급여임하지기관확장약물.분별관찰병감측기관내삽관응용호흡궤후1、4화6 h적호흡역학삼수(기도압력、기도조력화흉폐순응성).결과 Ⅰ조각개시간점적기도봉압、기도평태압이급기도조력명현저우Ⅱ조(P<0.05),이흉폐순응성명현고우Ⅱ조(P<0.05).결론 염산무을규미가명현강저COPD병인기관내삽관후적기도압력화기도조력,증가흉폐순응성.
Objective To investigate the effects of penehyclidine on respiratory mechanics after tracheal intubation in patients with chronic obstructive pulmonary disease. Methods Sixty-six patients with chronic obstructive pulmonary disease were divided randomely into two groups. Group Ⅰ (penehyclidine group, 33 cases) was intravenously injected 1 mg of penehyclidine before intubation, group Ⅱ (control group, 33 cases)was not given bronchodilator. Lung-chest walt compliance, airway pressure, and resistance were measured at 1 h,4 h,and 6 h after tracheal intubation. Results Patients in group Ⅰ had significantly both lower airway pressure and resistance and higher lung-chest wall compliance than group Ⅱ (P < 0. 05). Conclusion Penehyclidine produces higher lung-chest wall compliance and lower airway pressure and resistance in patients with chronic obstructive pulmonary disease.